scispace - formally typeset
G

Gisa Tiegs

Researcher at University of Hamburg

Publications -  81
Citations -  3061

Gisa Tiegs is an academic researcher from University of Hamburg. The author has contributed to research in topics: Immune system & Inflammation. The author has an hindex of 25, co-authored 81 publications receiving 2391 citations.

Papers
More filters
Journal ArticleDOI

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Andrea Cossarizza, +462 more
TL;DR: These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community providing the theory and key practical aspects offlow cytometry enabling immunologists to avoid the common errors that often undermine immunological data.
Journal ArticleDOI

Immune tolerance: what is unique about the liver.

TL;DR: An interesting observation in this context is that knockout of IL-10 or PD-L1 (or the receptor PD-1) does not necessarily result in inflammatory liver damage whereas transgenic inhibition of TGFbeta signaling induces liver disease in mice resembling chronic cholangitis.
Journal ArticleDOI

Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells

TL;DR: This review will focus on the communication between classical and nonclassical APCs and lymphocytes in the liver in tolerance induction and will discuss recent insights into the role of innate lymphocyte in this process.
Journal ArticleDOI

Acetaminophen/paracetamol: A history of errors, failures and false decisions.

TL;DR: It appears timely to reassess the risk/benefit ratio of paracetamol, probably one of the most dangerous compounds in medical use, causing hundreds of deaths in all industrialized countries due to acute liver failure (ALF).
Journal ArticleDOI

The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response.

TL;DR: The antioxidant biliverdin reduces HCV replication in vitro by triggering the antiviral interferon response and might improve HCV therapy in the future.